4 completed, 3 terminated, 2 withdrawn. 9 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Completed 4, Terminated 3, Withdrawn 2 |
Follow COVID: new trials by email Literature Review of COVID trials Research Report on COVID
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Sodium bicarbonate, Standard of Care - COVID, Coronavirus | Phase 4 | Terminated | West Virginia University | 3 | 2020-10-05 | 2023-12-22 |
| Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism TNKase, Placebo, Enoxaparin - Pulmonary Embolism, COVID | Phase 4 | Terminated | Cedars-Sinai Medical Center | 2 | 2020-09-08 | 2021-10-26 |
| Cholecalciferol to Improve the Outcomes of COVID-19 Patients Vitamin D, Placebo - COVID | Phase 4 | Completed | Vitamin D Study Group | 218 | 2020-08-11 | 2021-07-30 |
| OPV as Potential Protection Against COVID-19 oral polio vaccine + information, Information - Poliovirus Vaccine, Oral, COVID | Phase 4 | Completed | Bandim Health Project | 3729 | 2020-07-15 | 2026-04-07 |
| Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19 Sofosbuvir and Ledipasvir, Nitazoxanide - COVID | Phase 4 | Completed | Assiut University | 240 | 2020-07-15 | 2020-11-12 |
| Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19 Enoxaparin - COVID, Thrombosis | Phase 4 | Completed | Central Hospital, Nancy, France | 1000 | 2020-05-13 | 2023-08-07 |
| Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19 Camostat Mesilate, Placebo, Hydroxychloroquine - COVID | Phase 4 | Withdrawn | Heinrich-Heine University, Duesseldorf | 2020-05-01 | 2020-12-21 | |
| The Use of Tadalafil in Confirmed COVID-19 Pneumonia. Tadalafil Pill - COVID, Sars-CoV2 | Phase 4 | Withdrawn | Santa Barbara Cottage Hospital | 2020-04-20 | 2021-07-02 | |
| Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease Valsartan (Diovan), Placebo oral tablet - Acute Respiratory Distress Syndrome, SARS-CoV-2 | Phase 4 | Terminated | Radboud University Medical Center | 23 | 2020-04-17 | 2021-09-24 |
COVID-19 (2) · Coronavirus Infections (2) · Pulmonary Embolism (2) · Respiratory Distress Syndrome (2) · Acute Kidney Injury (1) · Respiratory Insufficiency (1) · Severe Acute Respiratory Syndrome (1) · Thrombosis (1) · Venous Thromboembolism (1) · Venous Thrombosis (1)
Respiratory Tract Diseases (6) · Lung Diseases (5) · Coronaviridae Infections (3) · Infections (3) · Nidovirales Infections (3) · RNA Virus Infections (3) · Respiration Disorders (3) · Virus Diseases (3) · Cardiovascular Diseases (2) · Embolism (2) · Embolism and Thrombosis (2) · Pneumonia (2) · Pneumonia, Viral (2) · Respiratory Tract Infections (2) · Vascular Diseases (2)
Enoxaparin (2) · Cholecalciferol (1) · Dalteparin (1) · Heparin (1) · Heparin, Low-Molecular-Weight (1) · Hydroxychloroquine (1) · Nadroparin (1) · Poliovirus Vaccine, Oral (1) · Sodium Bicarbonate (1) · Standard of Care (1) · Tadalafil (1) · Tenecteplase (1) · Therapeutics (1) · Tinzaparin (1) · Valsartan (1)
Assiut University (1) · Bandim Health Project (1) · Cedars-Sinai Medical Center (1) · Central Hospital, Nancy, France (1) · Heinrich-Heine University, Duesseldorf (1) · Radboud University Medical Center (1) · Santa Barbara Cottage Hospital (1) · Vitamin D Study Group (1) · West Virginia University (1)
United States (2) · Argentina (1) · Egypt (1) · France (1) · Guinea-Bissau (1) · Netherlands (1)
Ane Fisker, MD, PhD (1) · Ankit Sakhuja, MD (1) · Carlos Tajer, MD (1) · El Mehdi Siaghy (1) · Felipe Inserra, MD (1) · Haidi K Ramadan, PhD (1) · Javier Mariani, MD (1) · Laura Antonietti, MD (1) · Mohamed El Kassas, PhD (1) · Mohammed A Medhat, PhD (1) · Niels van Royen, MD PhD (1) · Victor E Tapson, MD (1) · Walter Manucha, PhD (1)
PMID 32422305, PMID 32512291, PMID 33502773, PMID 33522946, PMID 35244208, PMID 35622854, PMID 36193229, PMID 37350990